CD274 and cancer: These agents inhibit DNA repair mechanisms, leading to synthetic lethality in HR-deficient cancer cells, while also modulating immune pathways like STING and PD-L1, which may improve the efficacy of immune checkpoint inhibitors (ICIs) such as pembrolizumab [43,44].